Innovative Medicines based on ImmunoModulatory Biologics
Total31
(May 10, 2022) ‘OX40LxTNFα’ bispecific antibody project of IMBiologics funded by KDDF
2022-08-30
(September 1, 2021) IMBiologics successfully closes series A financing round with 13B KRW
2022-03-07
(January 19, 2021) IMBiologics raises 4B KRW seed round to accelerate R&D activities
(November 20, 2020) IMBiologics inks a worldwide exclusive licensing deal for anti-OX40L/TNF BsAb